[{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Trevena \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ CBC Group"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Trevena","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Trevena","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Trevena"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Jiangsu Nhwa Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Trevena \/ Jiangsu Nhwa Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Jiangsu Nhwa Pharmaceutical"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Trevena","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Trevena \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Trevena","sponsor":"Alcami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Trevena","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Trevena"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Oliceridine","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Oliceridine Fumarate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Oliceridine Fumarate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oliceridine Fumarate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Lotus Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Trevena \/ Lotus Clinical Research"},{"orgOrder":0,"company":"Trevena","sponsor":"Kestrel Biologic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oliceridine Fumarate","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Kestrel Biologic","highestDevelopmentStatusID":"8","companyTruncated":"Trevena \/ Kestrel Biologic"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Oliceridine Fumarate","moa":"Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"TRV250","moa":"Opioid receptor delta (OPRD1)","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"TRV734","moa":"Opioid receptor mu (MOP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"TRV734","moa":"Opioid receptor mu (MOP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TRV045","moa":"S1P1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Imperial College London","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trevena \/ Trevena","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Trevena"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ National Institutes of Health"},{"orgOrder":0,"company":"Trevena","sponsor":"Imperial College London","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Imperial College London","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Imperial College London"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Trevena \/ Undisclosed"},{"orgOrder":0,"company":"Trevena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"TRV027","moa":"Type-1 angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Trevena","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Trevena \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Trevena \/ Undisclosed"}]
	
		
			
Find Clinical Drug Pipeline Developments & Deals by Trevena 
		
	 
	
	
		
								
						
					
					
						
					
							
				
									
						
							
															
									Filters
										 
									
										× 
										FILTER:
										
																									
															
																Company Name 
																															
															
														 
																												
															Year  
															
														 
																												
															DEALS // DEV. 
															
														 
																												
															Country 
															
														 
																												
															
																Sponsor 
																															
															
														 
																												
															Therapeutic Area 
															
														 
																												
															Study Phase 
															
														 
																												
															Deal Type 
															
														 
																												
															Product Type 
															
														 
																												
															Dosage Form 
															
														 
																												
															Lead Product 
															
														 
																												
															Target